2 results
Approved WMORecruiting
Part A: To determine the recommended phase 2 dose and schedule of the RMC-4630 and LY3214996 combination in patients with KRASm advanced CRC, NSCLC and PDAC.Part B: To determine the safety and tolerability of RMC-4630 in combination with LY3214996…
Approved WMOCompleted
Primary Objective:To demonstrate noninferiority of ACRYSOF IQ PanOptix presbyopia-correcting IOL Model TFNT00 to the AT LISA tri IOL Model 839MP in mean photopic binocular uncorrected intermediate (60 cm) visual acuity at Visit 4A.Secondary…